FIELD: medicine; pharmaceuticals.
SUBSTANCE: invention refers to pharmaceutical industry, namely to an intranasal composition for treating allergic rhinitis. What is presented is an intranasal composition for treating allergic rhinitis, containing an effective amount of a cationic dendrimer peptide of formula (Arg)8(Lys)4(Lys)2Lys-Ala-Cys-NH2, which is in the basic non-salt form (b-LTP), serving as carrier, and a mixture of siRNA molecules suppressing IL-13 and IL-4 gene expression, represented by sequences GGACCUGCUCUUACAUUUAtt and AAAGAUGUCUGUUACGGUCtt, respectively, wherein the weight ratio of b-LTP to the siRNA molecule mixture is equal to 12.5:1, and the number of siRNA molecules in the mixture is the same.
EFFECT: disclosed composition is effective in inhibiting expression of a target gene.
1 cl, 12 dwg, 4 tbl, 4 ex
| Title | Year | Author | Number |
|---|---|---|---|
| COMPOSITION FOR INTERLEUKINE-4 CYTOKINE GENE SILENCING | 2014 |
|
RU2563989C1 |
| MEAN FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS TO CELLS OF MAMMALS | 2014 |
|
RU2572575C1 |
| APPLICATION OF COMPOSITION CONSISTING OF CATIONIC LTP PEPTIDE AND MOLECULES OF RNA AGAINST RESPIRATORY VIRUSES | 2015 |
|
RU2609857C1 |
| PEPTIDES FOR INTRACELLULAR DELIVERY OF NUCLEIC ACIDS | 2020 |
|
RU2771605C2 |
| COMBINED DRUG WITH ANTIVIRAL EFFECT AGAINST NEW SARS-COV-2 CORONAVIRUS | 2021 |
|
RU2746362C1 |
| METHOD FOR PREVENTING AND TREATING BRONCHIAL ASTHMA, COMPLICATING RESPIRATORY VIRAL INFECTIONS AND OTHER RESPIRATORY INFLAMMATORY DISEASES | 2012 |
|
RU2526146C2 |
| METHOD FOR ALLERGIC BRONCHIAL ASTHMA TREATMENT, BASED ON CYTOKINES IL-4 AND IL-13 GENES EXPRESSION INHIBITION USING SIRNA MOLECULES | 2016 |
|
RU2615463C1 |
| METHOD FOR ASSESSMENT OF EFFICIENCY OF ALLERGEN-SPECIFIC IMMUNOTHERAPY IN ALLERGIC RHINITIS | 2019 |
|
RU2700788C1 |
| siRNA AND THEIR USE IN METHODS AND COMPOSITIONS FOR INHIBITING EXPRESSION OF ORAI1 GENE | 2014 |
|
RU2689607C2 |
| LABELLED DENDRIMER PEPTIDES | 2016 |
|
RU2611399C1 |
